cariprazine


( Last Updated : May 25, 2022)
Generic Name:
cariprazine
Project Status:
Active
Therapeutic Area:
Schizophrenia
Manufacturer:
Allergan (an AbbVie Company).
Brand Name:
Vraylar
Project Line:
Reimbursement Review
Project Number:
SR0708-000
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
For the acute and long-term maintenance of schizophrenia in adults.
Fee Schedule:
Schedule A
Indications:
For the treatment of schizophrenia in adults.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
th scope="row">Expert committee meeting (initial)

Key Milestones2

Call for patient/clinician input open01-Oct-21
Call for patient/clinician input closed22-Nov-21
Clarification:

- Patient input submission received from Institute for Advancements in Mental Health

Submission received29-Oct-21
Submission accepted12-Nov-21
Review initiated15-Nov-21
Draft CADTH review report(s) provided to sponsor for comment03-Feb-22
Deadline for sponsors comments14-Feb-22
CADTH review report(s) and responses to comments provided to sponsor11-Mar-22
23-Mar-22
Draft recommendation issued to sponsor27-Apr-22
Draft recommendation posted for stakeholder feedback05-May-22
End of feedback period19-May-22
Clarification:

- Reconsideration: major revisions requested by sponsor